anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Bupivacaine
Trial phase: Phase 3
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 93
Group description: It will be used bupivacaine in surgical site prior surgery (25 mg). At least 10 minutes before skin incision.

Bupivacaine: It will be used as a analgesic dose in surgical site before surgery.
Eligibility criteria:
Inclusion Criteria:

Patient with afiliation to IMSS
Patient with ankle fracture that requires surgical treatment with open reduction and internal fixation
Patient that accept to participate in the study whit a sign of document.

Exclusion Criteria:

Politrauma patients (Patients with another fracture)
Patients who dont accept to participate in the study
Neuropathy in inferior limps that limits pain perception
Open ankle fractures
Intervention: Ropivacaine
Trial phase: Phase 3
ATC code: N01BB09
SMILES: CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 93
Group description: It will be used ropivacaine in surgical site prior surgery (37.5 mg). At least 10 minutes before skin incision.

Ropivacaine: It will be used as a analgesic dose in surgical site before surgery.
Eligibility criteria:
Inclusion Criteria:

Patient with afiliation to IMSS
Patient with ankle fracture that requires surgical treatment with open reduction and internal fixation
Patient that accept to participate in the study whit a sign of document.

Exclusion Criteria:

Politrauma patients (Patients with another fracture)
Patients who dont accept to participate in the study
Neuropathy in inferior limps that limits pain perception
Open ankle fractures
Intervention: Tolcapone
Trial phase: Phase 2
ATC code: N04BX01
SMILES: Cc1ccc(C(=O)c2cc(O)c(O)c([N+](=O)[O-])c2)cc1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 12
Group description: Tolcapone 100 mg three times per day for three days Tolcapone 200 mg three times per day for five days

Individuals with the rs4680 val/val genotype
Eligibility criteria:
Inclusion Criteria:

Age 21-40 (to focus on an age group still on a trajectory of increasing alcohol consumption).
Meets Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) criteria for current Alcohol Use Disorder.
Currently not engaged in, and does not want treatment for, alcohol-related problems.
Able to read and understand questionnaires and informed consent.
Lives within 50 miles of the study site.
Able to maintain abstinence from alcohol for two days (without the aid of detoxification medications), as determined by self report and breathalyzer measurements.

Exclusion Criteria:

Current DSM-5 diagnosis of any other substance use disorder except Nicotine Use Disorder.
Any psychoactive substance use (except marijuana and nicotine) within the last 30 days, as indicated by self-report and urine drug screen. For marijuana, no use within the last seven days by verbal report and negative (or decreasing) urine tetrahydrocannibinol (THC) levels.
Current DSM-5 Axis I diagnosis, including major depression, panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder, bipolar affective disorder, schizophrenia, dissociative disorders, eating disorders, or any other psychotic or organic mental disorder.
Current suicidal ideation or homicidal ideation.
Need for maintenance or acute treatment with any psychoactive medication, including antiepileptic medications.
Currently taking medication known to affect alcohol intake (e.g., disulfiram, naltrexone, acamprosate, topiramate).
History of severe alcohol withdrawal (e.g., seizure, delirium tremens), as evidenced by self-report and assessment with Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar).
Clinically significant medical problems such as cardiovascular, renal, gastrointestinal, or endocrine problems that would impair participation or limit medication ingestion.
Past alcohol-related medical illness, such as gastrointestinal bleeding, pancreatitis, or peptic ulcer.
Current or past hepatocellular disease, as indicated by verbal report or elevations of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than the upper limit of the normal range at screening.
Females of childbearing potential who are pregnant (by urine human chorionic gonadotropin), nursing, or who are not using a reliable form of birth control.
Current charges pending for a violent crime (not including drinking while intoxicated).
Lack of a stable living situation.
Presence of ferrous metal in the body, as evidenced by metal screening and self-report.
Severe claustrophobia or morbid obesity that preclude placement in the MRI scanner.
History of head injury with > 2 minutes of unconsciousness.
Intervention: Tolcapone
Trial phase: Phase 2
ATC code: N04BX01
SMILES: Cc1ccc(C(=O)c2cc(O)c(O)c([N+](=O)[O-])c2)cc1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 16
Group description: Tolcapone 100 mg three times per day for three days Tolcapone 200 mg three times per day for five days

Individuals with the rs4680 val/met genotype
Eligibility criteria:
Inclusion Criteria:

Age 21-40 (to focus on an age group still on a trajectory of increasing alcohol consumption).
Meets Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) criteria for current Alcohol Use Disorder.
Currently not engaged in, and does not want treatment for, alcohol-related problems.
Able to read and understand questionnaires and informed consent.
Lives within 50 miles of the study site.
Able to maintain abstinence from alcohol for two days (without the aid of detoxification medications), as determined by self report and breathalyzer measurements.

Exclusion Criteria:

Current DSM-5 diagnosis of any other substance use disorder except Nicotine Use Disorder.
Any psychoactive substance use (except marijuana and nicotine) within the last 30 days, as indicated by self-report and urine drug screen. For marijuana, no use within the last seven days by verbal report and negative (or decreasing) urine tetrahydrocannibinol (THC) levels.
Current DSM-5 Axis I diagnosis, including major depression, panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder, bipolar affective disorder, schizophrenia, dissociative disorders, eating disorders, or any other psychotic or organic mental disorder.
Current suicidal ideation or homicidal ideation.
Need for maintenance or acute treatment with any psychoactive medication, including antiepileptic medications.
Currently taking medication known to affect alcohol intake (e.g., disulfiram, naltrexone, acamprosate, topiramate).
History of severe alcohol withdrawal (e.g., seizure, delirium tremens), as evidenced by self-report and assessment with Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar).
Clinically significant medical problems such as cardiovascular, renal, gastrointestinal, or endocrine problems that would impair participation or limit medication ingestion.
Past alcohol-related medical illness, such as gastrointestinal bleeding, pancreatitis, or peptic ulcer.
Current or past hepatocellular disease, as indicated by verbal report or elevations of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than the upper limit of the normal range at screening.
Females of childbearing potential who are pregnant (by urine human chorionic gonadotropin), nursing, or who are not using a reliable form of birth control.
Current charges pending for a violent crime (not including drinking while intoxicated).
Lack of a stable living situation.
Presence of ferrous metal in the body, as evidenced by metal screening and self-report.
Severe claustrophobia or morbid obesity that preclude placement in the MRI scanner.
History of head injury with > 2 minutes of unconsciousness.
Intervention: Tolcapone
Trial phase: Phase 2
ATC code: N04BX01
SMILES: Cc1ccc(C(=O)c2cc(O)c(O)c([N+](=O)[O-])c2)cc1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 14
Group description: Tolcapone 100 mg three times per day for three days Tolcapone 200 mg three times per day for five days

Individuals with the rs4680 met/met genotype
Eligibility criteria:
Inclusion Criteria:

Age 21-40 (to focus on an age group still on a trajectory of increasing alcohol consumption).
Meets Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) criteria for current Alcohol Use Disorder.
Currently not engaged in, and does not want treatment for, alcohol-related problems.
Able to read and understand questionnaires and informed consent.
Lives within 50 miles of the study site.
Able to maintain abstinence from alcohol for two days (without the aid of detoxification medications), as determined by self report and breathalyzer measurements.

Exclusion Criteria:

Current DSM-5 diagnosis of any other substance use disorder except Nicotine Use Disorder.
Any psychoactive substance use (except marijuana and nicotine) within the last 30 days, as indicated by self-report and urine drug screen. For marijuana, no use within the last seven days by verbal report and negative (or decreasing) urine tetrahydrocannibinol (THC) levels.
Current DSM-5 Axis I diagnosis, including major depression, panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder, bipolar affective disorder, schizophrenia, dissociative disorders, eating disorders, or any other psychotic or organic mental disorder.
Current suicidal ideation or homicidal ideation.
Need for maintenance or acute treatment with any psychoactive medication, including antiepileptic medications.
Currently taking medication known to affect alcohol intake (e.g., disulfiram, naltrexone, acamprosate, topiramate).
History of severe alcohol withdrawal (e.g., seizure, delirium tremens), as evidenced by self-report and assessment with Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar).
Clinically significant medical problems such as cardiovascular, renal, gastrointestinal, or endocrine problems that would impair participation or limit medication ingestion.
Past alcohol-related medical illness, such as gastrointestinal bleeding, pancreatitis, or peptic ulcer.
Current or past hepatocellular disease, as indicated by verbal report or elevations of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than the upper limit of the normal range at screening.
Females of childbearing potential who are pregnant (by urine human chorionic gonadotropin), nursing, or who are not using a reliable form of birth control.
Current charges pending for a violent crime (not including drinking while intoxicated).
Lack of a stable living situation.
Presence of ferrous metal in the body, as evidenced by metal screening and self-report.
Severe claustrophobia or morbid obesity that preclude placement in the MRI scanner.
History of head injury with > 2 minutes of unconsciousness.
Intervention: Zafirlukast
Trial phase: Phase 2
ATC code: R03DC01
SMILES: COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 2
Group description: Zafirlukast

zafirlukast: Patients will begin treatment with zafirlukast on post-operative day one following placement of tissue expander(s) once determined safe from a surgical recovery standpoint. They will be continued on the standard dosing (20mg PO twice per day) of zafirlukast through expander fill (6-12 weeks, up to 18 weeks for women receiving radiation). Treatment will be stopped 48 hours prior to expander-implant exchange, which is equivalent to five half-lives of the drug. Patients will be seen every 1 to 2 weeks for expander fill, and will be assessed clinically based on the Baker classification system of capsular contracture every two weeks.
Eligibility criteria:
Inclusion Criteria:

Patients who are scheduled to undergo therapeutic or prophylactic mastectomy with immediate placement of tissue expanders and have a strong family history or hereditary cancer
Age ≥ 18 years
Zafirlukast is pregnancy category B. There are no adequate and well-controlled trials in pregnant women. Therefore, the effects of zafirlukast on the developing human fetus are unknown. For this reason, women of child-bearing potential must agree to use adequate contraception: 2 methods of birth control, prior to study entry ad for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately.
Ability to understand a written informed consent document, and the willingness to sign it
At least 4 weeks post-completion of chemotherapy

Adequate organ function within 14 days start of study start:

Absolute neutrophil count (ANC) ≥ 1.5 X 10^9/L
Hemoglobin (Hgb) ≥9g/dL
Platelets (plt) ≥ 100 x 10^9/L
Potassium within normal range, or correctable with supplements;
AST and ALT ≤2.5 x Upper Limit Normal (ULN) or ≤5.0 x ULN if liver tumor is present;
Serum total bilirubin ≤ 1.5 x ULN
Serum creatinine ≤ 1.5 x ULN, or 24-hr clearance ≥ 60ml/min

Exclusion Criteria:

Any significant medical condition, laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study
Currently on a leukotriene inhibitor or used within the past 6 months
Prior chest wall radiation
Pregnant or breastfeeding

Hepatic impairment as defined by:

• AST(SGOT) > 2.5X institutional ULN and ALT(SGPT) > 2.5X institutional ULN

Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
Intervention: Nicotine
Trial phase: Early Phase 1
ATC code: N07BA01
SMILES: CN1CCCC1c1cccnc1
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 30
Group description: Intravenous bolus of Lactated Ringer solution (30ml/kg) via 18ga IV catheter at wide open.

Lactated Ringer Solution: Fluid bolus of Lactated Ringer solution (30ml/kg).
Eligibility criteria:
Inclusion Criteria:

Healthy adult volunteers
18 years and older

Exclusion Criteria:

Pregnancy or currently breast-feeding
Prisoner
History of conditions associated with fluid overload: heart, renal or hepatic failure
Baseline serum lactate level >2.2mmol
Baseline creatinine > 1.5 mg/dL
Intervention: SODIUM CHLORIDE
Trial phase: Early Phase 1
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 30
Group description: Intravenous bolus of Normal Saline (30ml/kg) via 18ga IV catheter at wide open.

Normal Saline: Fluid bolus or Normal Saline (30ml/kg).
Eligibility criteria:
Inclusion Criteria:

Healthy adult volunteers
18 years and older

Exclusion Criteria:

Pregnancy or currently breast-feeding
Prisoner
History of conditions associated with fluid overload: heart, renal or hepatic failure
Baseline serum lactate level >2.2mmol
Baseline creatinine > 1.5 mg/dL
Intervention: Basmisanil
Trial phase: Phase 2
SMILES: Cc1onc(-c2ccc(F)cc2)c1COc1ccc(C(=O)N2CCS(=O)(=O)CC2)cn1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 54
Group description: Participants received Basmisanil 80 mg orally twice daily (BID) for 24 weeks.
Eligibility criteria:
Inclusion Criteria:

Diagnosis of schizophrenia of any type utilizing the Mini International Neuropsychiatric Interview and diagnostic and statistical manual of mental disorders, fifth edition (DSM-5) direct clinical assessments, family informants and past medical records
Evidence of stability of symptoms for 3 months at screening, that is, without hospitalizations for schizophrenia or increase in level of psychiatric care due to worsening of symptoms of schizophrenia
Participants with schizophrenia clinical symptom severity defined by the following: hallucinatory behavior item score less than or equal to (</=) 5 and a delusion item score </= 5 of the PANSS
Participants on a stable regimen of antipsychotic therapy for at least 3 months at screening and receiving no more than two antipsychotics

Exclusion Criteria:

Participants with current DSM-5 diagnosis other than schizophrenia including bipolar disorder, schizoaffective disorder and major depressive disorder
Clinically significant neurological illness or significant head trauma that affects cognitive function, in the judgment of the principal investigator
Full scale intelligence quotient </=65 on the Wechsler Abbreviated Scale of Intelligence at screening
Positive result at screening for hepatitis B, hepatitis C, or human immunodeficiency virus-1 and 2
Moderate to severe substance use disorder (other than nicotine or caffeine), as defined by the DSM-5, within the last 12 months
Suicide attempt within 1 year or currently at risk of suicide in the opinion of the Investigator
Intervention: Basmisanil
Trial phase: Phase 2
SMILES: Cc1onc(-c2ccc(F)cc2)c1COc1ccc(C(=O)N2CCS(=O)(=O)CC2)cn1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 78
Group description: Participants received Basmisanil 240 mg orally twice daily (BID) for 24 weeks.
Eligibility criteria:
Inclusion Criteria:

Diagnosis of schizophrenia of any type utilizing the Mini International Neuropsychiatric Interview and diagnostic and statistical manual of mental disorders, fifth edition (DSM-5) direct clinical assessments, family informants and past medical records
Evidence of stability of symptoms for 3 months at screening, that is, without hospitalizations for schizophrenia or increase in level of psychiatric care due to worsening of symptoms of schizophrenia
Participants with schizophrenia clinical symptom severity defined by the following: hallucinatory behavior item score less than or equal to (</=) 5 and a delusion item score </= 5 of the PANSS
Participants on a stable regimen of antipsychotic therapy for at least 3 months at screening and receiving no more than two antipsychotics

Exclusion Criteria:

Participants with current DSM-5 diagnosis other than schizophrenia including bipolar disorder, schizoaffective disorder and major depressive disorder
Clinically significant neurological illness or significant head trauma that affects cognitive function, in the judgment of the principal investigator
Full scale intelligence quotient </=65 on the Wechsler Abbreviated Scale of Intelligence at screening
Positive result at screening for hepatitis B, hepatitis C, or human immunodeficiency virus-1 and 2
Moderate to severe substance use disorder (other than nicotine or caffeine), as defined by the DSM-5, within the last 12 months
Suicide attempt within 1 year or currently at risk of suicide in the opinion of the Investigator
Intervention: Acthargel
Trial phase: Phase 4
SMILES: CSCCC(NC(=O)C(CO)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(N)CO)C(=O)NC(CCC(=O)O)C(=O)NC(Cc1cnc[nH]1)C(=O)NC(Cc1ccccc1)C(=O)NC(CCCNC(=N)N)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NCC(=O)NC(CCCCN)C(=O)N1CCCC1C(=O)NC(C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)N1CCCC1C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(Cc1ccc(O)cc1)C(=O)N1CCCC1C(=O)NC(CC(N)=O)C(=O)NCC(=O)NC(C)C(=O)NC(CCC(=O)O)C(=O)NC(CC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(Cc1ccccc1)C(=O)N1CCCC1C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(Cc1ccccc1)C(=O)O)C(C)C)C(C)C)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 86
Group description: Participants receive Acthar Gel
Eligibility criteria:
Inclusion Criteria:

To be eligible to participate in this trial, a patient must:

Have a diagnosis of SLE according to 4 of the American College of Rheumatology revised criteria
Have active SLE
Have moderate to severe rash and/or arthritis as demonstrated by BILAG-2004 score A or B in the mucocutaneous and/or musculoskeletal body systems at both Screening and Randomization Visits

Have a documented history or screening result of

positive antinuclear antibody (ANA), OR
elevated anti-dsDNA or extractable nuclear antigen (ENA) antibodies

Have been on prednisone (or prednisone equivalent) before the screening visit:

at least 8 weeks, and
at a stable dose of 7.5 mg to 30 mg for at least 4 weeks

Exclusion criteria:

A patient is not eligible to participate if he/she:

Has a history of sensitivity to adrenocorticotropic hormone (ACTH) preparations or porcine products
Has active lupus nephritis
Has active central nervous system (CNS) manifestations of SLE
Intervention: Fulvestrant
Trial phase: Phase 2
ATC code: L02BA03
SMILES: [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])c3ccc(O)cc3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H]
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 32
Group description: 500mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC) and 160mg of Enzalutamide will be given, in conjunction with Fulvestrant, PO daily.

Fulvestrant with Enzalutamide: 500mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC) and 160mg of Enzalutamide will be given PO daily. Patients will receive a tumor biopsy at the start of treatment and 4 weeks after the start of treatment, with an optional 3rd biopsy at the end treatment.
Eligibility criteria:
Inclusion Criteria:

ER+ Her2- breast cancer
Metastatic
Female, at least 18 years of age
Candidate for fulvestrant therapy - patients who have started fulvestrant may enter this trial if within 3 months of starting fulvestrant
Measurable or evaluable by RECIST 1.1
ECOG PS 0-2
Able to swallow study drug and comply with study requirements
Tumor available for fresh biopsy (two biopsies - pretreatment as regards enzalutamide, and during treatment at 4 weeks). The patient will be also be asked if they would be willing to provide a third biopsy at time of progression.
If patient is pre- or peri- menopausal, then will need to have concurrent ovarian suppression. Patients may have already gotten the loading dose of ovarian suppression. Pre- or peri- menopausal subjects must have a negative urine pregnancy test confirmed at screening.
ANC >1000/uL and platelets >75,000/uL at screening visit
Total bilirubin < 1.5 times upper limit of normal (ULN) at the screening visit unless an alternate nonmalignant etiology exists (eg, Gilbert's disease)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 times ULN or < 5 times ULN if patient has documented liver metastases
Creatinine < 1.5 times ULN
INR < 1.5 times ULN, or if on warfarin, can safely transition off for biopsy
Willing to donate blood for research at 4 time points
Written informed consent obtained prior to biopsies and blood samples
Agreement to exercise appropriate use of contraception. Subjects should use 2 acceptable methods of birth control (one of which must include a condom as a barrier method of contraception) starting at the time of screening for an enzalutamide study and continuing throughout the course of treatment and for at least three months after enzalutamide is discontinued.

Exclusion Criteria:

Current or previously treated brain or leptomeningeal metastases
History of seizures
Prior treatment with an anti-androgen (abiraterone, ARN-509, bicalutamide, enzalutamide, ODM-201, TAK-448, TAK-683, TAK-700, VT-464)
Systemic estrogens or androgens within 14 days before initiating therapy. Vaginal estrogens are allowed if necessary for patient comfort.